Please ensure Javascript is enabled for purposes of website accessibility

Aktis Oncology

The Wall street sign hangs outside the New York Stock Exchange (NYSE) building on Tuesday following Monday’s broad sell off in New York City, U.S., March 11, 2025. REUTERS/Shannon Stapleton
Jan 7, 2026

Aktis Oncology secures Lilly as anchor investor for upsized US IPO

Jan 7 (Reuters) – Cancer drug developer Aktis Oncology said on Wednesday it was targeting a valuation of up to $945.4 million in its upsized initial public offering, signaling strong investor demand for 2026’s first U.S. listing. The Boston, Massachusetts-based company has also drawn in Eli Lilly to anchor the IPO, with the pharma giant […]

YOUR NEWS.
YOUR INBOX.
DAILY.

By subscribing you agree to our Privacy Policy.